ReviewInternational journal of clinical oncology2026
Ocular toxicities associated with anticancer drug therapy in Asian patients: a literature review and practical management recommendations for non-ophthalmologic settings.
Review in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOcular toxicities associated with anticancer therapies, including cytotoxic chemotherapy, hormonal agents, molecular targeted therapies, immune checkpoint inhibitors, and antibody-drug conjugates, are increasingly recognized and may substantially impair visual function and quality of life. However, ethnicity-specific data for Asian populations and practical management strategies applicable to non-ophthalmologic settings remain limited.
methodsA literature review of publications up to December 2025 was conducted using PubMed to identify studies reporting incidence, mechanisms, prevention, or management of anticancer drug-associated ocular toxicities in Asian patients. Based on the extracted evidence, practical management recommendations applicable to healthcare settings without on-site ophthalmologists were developed.
resultsOverall, 155,202 manuscripts were identified, of which 70 studies met the inclusion criteria. Most of these manuscripts were case reports, retrospective analyses, or expert recommendations, with few prospective or interventional studies. Ocular toxicities varied by anticancer drug class and involved the ocular surface, retina, optic nerve, and immune-mediated inflammation. Incidence and clinical characteristics differed across drug classes, and ethnicity-specific data for Asian patients were inconsistently reported. Based on these findings, a symptom-based management algorithm applicable to non-ophthalmologic settings was developed, emphasizing early recognition of ocular toxicities, supportive care (e.g., artificial tears and topical steroids) initiation, treatment interruption for persistent or moderate symptoms, and timely ophthalmology referral for visual acuity decline or refractory cases.
conclusionsThis review summarizes current evidence on anticancer drug-associated ocular toxicities in Asian patients and proposes pragmatic recommendations and an algorithm to support their early recognition and management in non-ophthalmologic settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.